- Home
- SILO vs MBIO Comparison
SILO vs MBIO Comparison
Compare SILO & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILO | MBIO |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SILO | MBIO |
|---|---|---|
| Price | $0.29 | $0.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 103.7K | ★ 432.4K |
| Earning Date | 03-30-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,102.00 | N/A |
| Revenue This Year | $1.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.53 |
| 52 Week High | $1.57 | $7.00 |
Technical Indicators
Market Signals| Indicator | SILO | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 43.04 |
| Support Level | $0.29 | $0.53 |
| Resistance Level | $0.33 | $1.10 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 19.14 | 66.13 |
Price Performance
Historical ComparisonAbout SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.